




Income Statement Summary

Record-high sales and profits

Millions of yen	2022 Full year				



Achieved



Partnership with Astellas Pharma


Joint development with Astellas Pharma

Using proprietary technology, develop multiple pharmaceutical products that degrade proteins causing



Toward the Future

No




FY2024 Guidance

Significant r












GNI market capitalization 181.9 billion yen
Gyre market capitalization 321.4 billion yen

Net cash





Cullgen Pipeline





